Peripheral artery disease affects the legs of claudicating patients in a diffuse manner irrespective of the level of the arterial tree primarily involved

INTRODUCTION

Intermittent claudication is the most common manifestation of peripheral artery disease (PAD)[1]. Claudication is defined as walking-induced, ischemic leg pain that is most commonly described by the patient as severe muscle cramping, tightness, aching, and/or fatigue[2]. Claudication results in severely decreased functional ability[3] and quality of life[4] and is associated with increased risk for the occurrence of other cardiovascular related events and mortality[5]–[7].

Patients with PAD walk with an abnormal gait pattern compared to healthy, age matched controls[8], [9]. The majority of these gait abnormalities are present from the first step the patients take, well before the onset of claudication, and become more severe when claudication discomfort begins[10], [11]. Research from our group and others has shown that the abnormal gait pattern is characterized by slower walking speed, decreased cadence, increased stance time, and shorter stride lengths compared to healthy, age-matched controls[12]. Furthermore, patients with PAD walk with altered joint angles[12], [13] and reduced joint torques[10], [14] and powers[10], [14], [15] around the ankle, knee, and hip joints compared to their healthy counterparts.

Atherosclerotic stenoses/occlusions can occur at any or multiple levels throughout the arterial tree supplying the leg, restricting blood flow to the muscles responsible for movement at the hip, knee, and ankle joints. These blockages are typically grouped into the following general levels: aortoiliac (AI), femoropopliteal (FP), tibial, and multi-level disease (MLD)[16]. Aortoiliac disease can produce claudication symptoms in all major muscle groups (calves, thighs and buttocks) of the leg [17], [18]. Femoropopliteal disease can produce claudication symptoms in the muscles of the calves[17]. Tibial disease may also produce claudication symptoms in the muscles of the calf. Multi-level atherosclerosis is associated with vascular narrowing/occlusion in more than one level of the arterial tree of the leg. Patients with MLD tend to have worse hemodynamic compromise, than patients with single level disease, and they can experience claudication symptoms in all major muscle groups of the leg including those of the calves, thighs and buttocks. However, they usually experience claudication pain distal to the most affected arterial segment[18] [19].

Arterial blockages and the ischemia and ischemia/reperfusion they generate in the muscles they affect, produce an ischemic myopathy in the legs of PAD patients. At the histological level the principal characteristics of the myopathy are myofiber degeneration and fibrosis of the extracellular matrix and microvessels of the affected muscles[20]–[25], [64]. At the biochemical level the myopathy is characterized by oxidative damage, mitochondrial dysfunction, cytoskeletal disintegration and a characteristic upregulation of cytokines[20], [22], [26]–[31]. The myopathy of PAD in association with exercise-induced ischemia produce the, familiar to all vascular practitioners, abnormal muscle performance and metabolically inefficient walking pattern of claudicating patients[10]–[12], [14], [15], [32]. Because the level of occlusive disease usually determines the muscle group that is affected by the discomfort of claudication, it is possible that disease level may also play a primary role in the patient’s walking biomechanics and determine a patient’s compensation strategies during gait. Specifically, it is likely that different levels of occlusive disease produce ischemia, myopathy, and functional compromise of different muscle groups in the PAD legs which then results in distinctive gait patterns. It is also possible that as different muscle groups are affected, the patient’s muscular and neurological systems respond by alleviating the load placed on the more affected muscle groups while increasing the contribution of less affected muscles in an attempt to reduce pain and improve metabolic efficiency. Investigating the influence of disease level on a patient’s gait may provide pivotal information regarding the pathophysiology of claudication and the development of each patient’s walking impairments. By identifying if and how the level of vascular stenosis/occlusion affects the contributions of the muscles that move particular joints, and results in specific gait abnormalities in individuals with PAD, clinicians and therapists may be better able to understand the type and degree of functional limitation produced by different patterns of occlusive disease. This knowledge may help with the development of treatment plans that target specific muscles such as the ankle or knee or hip flexors/extensors based on the vascular stenosis/occlusion level and may provide the basis for physical therapy and exercise interventions that are more patient-specific and possibly more effective in rehabilitating each patient’s PAD limitations.

In this study we tested the hypothesis that the level of arterial stenosis/occlusion would uniquely impair the net muscle contributions, walking pattern and overall walking ability between patients with different levels of disease and compared to healthy controls. More specifically we aimed to determine if different levels of vascular stenosis/ occlusion uniquely affect walking patterns, as described by objective kinematic, kinetic, spatiotemporal gait parameters, and six minute walk distances and by subjective measurements acquired through the Walking Impairment Questionnaire (WIQ) and the Medical Outcomes Study Short Form 36 Health Survey (SF-36). Furthermore, we sought to determine if claudicating patients can be classified according to their level of disease based on their pattern of gait impairments.

METHODS

RESULTS

DISCUSSION

Our data using advanced biomechanical analyses and standard clinical and quality of life assessments, indicate that different levels of arterial disease present with very different patterns of symptoms affecting the different muscle groups of the lower extremity but produce similar degrees of impairments across all muscle groups of the leg and in the walking patterns and walking distances of claudicating PAD patients. We found that PAD patients with different levels of vascular stenosis/occlusion have very similarly affected gait patterns (as described by kinematic, kinetic, and spatiotemporal gait parameters) and walking distances (measured with six-minute walk test) and very similar subjective impairments (measured with WIQ and SF-36). Patients with AI, FP and MLD disease all had similarly impaired biomechanics, compared to control, around their ankle, knee and hip joints (the muscle groups flexing and extending the ankle, knee and hip are similarly impaired in all PAD groups). None of the investigated biomechanical parameters differed between level of disease groups in the pain free walking condition, with minimal differences occurring in the claudicating condition. Moreover, when trying to determine if patients can be classified according to their level of disease based on gait impairments, and if quality of life information acquired through the WIQ and SF-36, differed across groups of patients with different levels of disease, we found that the model performed well in identifying healthy controls in both the pain (83.3% classification accuracy) and pain free (76.0% classification accuracy) conditions and that the model can also accurately classify individuals in the MLD group during the pain condition (88.6% classification accuracy), but had trouble differentiating between PAD subject groups in all other scenarios. Previous work has shown that gait impairments are present from the first steps a PAD patient takes while walking pain-free and are augmented when the patient starts experiencing claudication symptoms [10], [11]. This augmentation of walking impairments, especially in what is traditionally the lowest functioning group (MLD)[19], may help explain why the discriminant analysis was more accurate in identifying subject groupings during the pain condition compared to pain-free walking. The conclusion of no differences between level of disease groups is reinforced by the fact that all WIQ subscales scores were statistically similar between PAD groups. The SF-36 scores were also similar across level of disease groups with the only differences identified being in the subscales of pain between the FP and MLD groups and emotional health between the AI and MLD groups.

The results of the current study are not in accord with our hypothesis that different levels of occlusive disease uniquely affect the muscle contributions within the PAD legs and therefore produce distinctive differences in the way claudicating patients walk. Although it may be understandable that claudication produced by occlusions that are similar in hemodynamic significance impair walking distances and quality of life parameters in a similar fashion irrespective of the level of the arterial tree involved, it is difficult to explain how this would also be the case for gait biomechanics. For example, it is difficult to understand how a patient with FP disease presenting with calf claudication can have similarly affected knee and hip biomechanics reflecting similarly compromised thigh and buttock muscle contributions as a patient with AI or MLD disease presenting with calf, thigh and buttock claudication. However, this is exactly what our data demonstrate. More specifically all patients with FP disease present with claudication symptoms affecting only their calves while 22 out of 25 AI patients and 34 of 49 MLD patients present with claudication symptoms that also affect the thigh and/or buttock musculature, yet gait biomechanics were similar across the three groups. Our findings on level of symptoms confirms the well-known fact that different levels of arterial occlusive disease produce symptoms in different muscle groups (calves, thighs, buttocks) of the leg [17], [18] which led us to theorize that different levels of occlusive disease produce ischemia, myopathy and functional compromise of different muscle groups and this would result in distinctive biomechanical patterns around the ankle, knee and hip joints. The absence of difference in gait biomechanical patterns was surprising to us and raises several considerations that may explain our findings.

A possible explanation may be that AI, FP and MLD all affect the calf and foot of the patient and that the affected foot and calf dominate the biomechanical behavior of the entire leg [42]. This can lead to ankle movement impacting knee and hip mechanics. The stance phase of walking is a closed chain movement, so movement impairments at the ankle must produce a corresponding response (and possibly an impairment) at the knee and/or hip. Additionally, the biarticular nature of certain hamstring, quadricep, and calf muscles, makes it likely that pain in the calves, thigh, or buttocks can impact mechanics at more than one joint.

It is also possible that what we consider to be hemodynamically insignificant (<30% diameter reduction) disease in an arterial segment is a significant contributor to the functional deterioration of the muscles supplied by this arterial segment. This may be because the disease becomes hemodynamically significant (either pressures drop or flow patterns change across the segment) when exercise initiates higher flows through the diseased segment, or because the atherosclerotic plaques (even though they are mild or minimal) produce cytokines, reactive oxygen species and pro-inflammatory products that then reach and adversely affect the corresponding muscle groups [43], [44]. This possibility may be of particular interest since the vast majority of patients with FP disease have atherosclerotic changes in their AI segment (eleven had mild, nine minimal and only three had no occlusive disease) and similarly, the majority of AI patients have atherosclerotic changes in their FP segment (eight had mild, eleven minimal and six no femoropopliteal occlusive disease) even though these changes are not hemodynamically significant (<30%). Essentially, one of the most important findings of our study is the very low prevalence of strictly one-level of PAD in claudicating patients. Our data suggest that PAD is an atherosclerotic process that presents as multilevel disease with certain arterial segments becoming involved with more hemodynamically significant stenoses than others and this multilevel disease affects the ischemic legs of PAD patients in a multilevel fashion impairing the performance of all leg muscles at the buttock, thigh, and calf level.

It is also possible that occlusive disease in a segment of the arterial tree changes the flow patterns in the segment above it and that such disturbed flow patterns may affect the health of the endothelium and all the layers of the arterial wall of the seemingly “normal” arterial segment and the muscles that are perfused by the segment. Related to this is the recently described increase in arterial stiffness in the arteries of PAD patients[45]–[47]. This may be promoted by disturbed flow which stimulates pro-inflammatory responses from endothelial cells and promotes atherosclerotic remodeling of affected arteries through lipid accumulation and elastin degradation[46]. The work by Abraham et al. supports this possibility because it demonstrates a substantial decrease in the resting and post exercise transcutaneous oxygen saturation of the skin over the buttocks both in patients with AI disease but also in a large number of patients without AI disease[48], [49].

Finally, while it is important to focus on the downstream damage PAD produces to the tissues of the affected lower limbs (due to ischemia and ischemia/reperfusion of the leg) we should also consider the, thus far poorly explored, effects of PAD to the rest of the body (mediated through the activation of metabolic, neural, or inflammatory pathways) as this may also explain some of our findings. In this process the ischemic limb distributes and communicates to the rest of the body, the adverse ischemic events it suffers several times during the day, every time the patient experiences leg ischemia with or without associated claudication symptoms. In this process a patient with FP disease and an ischemic calf can experience pathological changes and decreased performance of the ipsilateral non-ischemic thigh or pelvic musculature but also damage to other limbs and organs of the body. This may be an important pathway explaining how PAD can produce the increased morbidity and mortality that is so well documented for PAD patients [5]– [7]. The best evidence for a systemic effect of PAD comes from work showing that a single bout of exercise of the PAD legs produces a significant increase of biomarkers of oxidative stress (increased malondialdehyde, consumption of anti-oxidants)[50], increased inflammatory cells (white blood cells and neutrophils)[51], [52] and increased inflammatory cytokines (thromboxane, p-selectin, von Willebrand factor) in the blood and a significant activation of the sympathetic system of PAD patients. Of note, the group of Sinoway and Cauffman have shown in several elegant studies that it takes a few, low-intensity, contractions of the posterior calf muscles of PAD patients to produce significant sympathetic system activation and adverse effects on physiologic parameters like the heart rate, blood pressure and coronary and renal artery blood flow[53]–[55]. It is possible that sympathetic system activation by ischemia of the calf can adversely affect the blood flow and the health of the thighs and buttocks. It is likely that the increased local production of anaerobic metabolites, reactive oxygen species, and cytokines is a key mediator for the activation of the sympathetic loops that originate in the ischemic leg [56], [57]. These loops convey the injurious information to the brain, the limb itself, and the rest of body including limbs and organs [58].

Ankle power generation at push-off was the most significant contributor in determining subject classification (control versus PAD including AI, FP, or MLD) in both the pain and pain free conditions. This is likely due to the importance of the ankle plantarflexors in propelling the individual forward during walking. The plantarflexor muscles contribute approximately 50% of the positive work on the body’s center of mass during propulsion and more mechanical power than the hip and knee joints combined[42], [59]–[61]. Similar to previous studies, our results indicate patients with PAD display significantly lower power and torque outputs at the ankle compared to healthy controls, with augmented differences after the onset of claudication[10], [11], [14], [15], [62]. However, still no differences between patient groups were observed for this variable. Although all PAD groups had vascular stenosis/occlusion at or above the knee joint, resulting in all groups experiencing inadequate blood flow to the plantarflexor muscles, research has shown oxygen delivery to the muscles is not the only limiting factor in exercise performance for individuals with PAD[63]. Our group and others have extensively described that atherosclerotic blockages produce a state of ischemia and ischemia/reperfusion in the PAD legs which initiates oxidative stress/damage, mitochondrial dysfunction and cytokine upregulation, producing injury to all tissues including muscles, nerves, skin, and subcutaneous tissues [20], [31], [64]. Accumulating injury in the leg leads to progressive damage of muscle structure and function which in association with exercise-induced ischemia produce the limitation in walking ability known as claudication. The work of several laboratories including our own has demonstrated that this myopathy is closely related to leg function, daily activity, quality of life and mortality of PAD patients [7], [65]–[68].

One possible limitation to this study is how level of disease was assigned to each participant. Participants were assigned to a disease group based on the level of the arterial tree which had significant stenosis/occlusion (>30% diameter reduction) as determined by vascular surgeons using computerized tomographic angiographic imaging[35] [36]. Many of these participants had atherosclerotic disease in other areas of the leg but this disease was minimal (less than 10% diameter reduction) or mild (less than 30% diameter reduction). However, given the study results, the authors do not believe this could have changed the results of the study given no differences were found between any of the PAD groups.

CONCLUSION

Our data using advanced biomechanical analyses and standard clinical and quality of life assessments, indicate that different levels of arterial disease present with symptoms affecting different muscle groups of the lower extremity, but produce similar degrees of dysfunction in all muscle groups of the leg and in the walking patterns, distances, and impairments of PAD patients with claudication. PAD affects claudicating legs in a diffuse manner irrespective of the level of the arterial tree primarily involved. Several pathophysiologic parameters that have to do with the true nature of PAD as a multilevel disease and its complicated hemodynamics, neuropathy, myopathy, and systemic effects will need to be further researched to understand the diffuse manner in which PAD affects the legs of claudicating patients.